07 Jan 2001

Doxymono® 100 (Doxymono® 100/-200 Tabletten) - Deutschland

Updated: 07 Jan 2001

Doxymono® 100 | -200

Infektionen, verursacht durch Doxycyclin-empfindl. Krankheitserreger, z. B. d. Atemwege u. d. HNO-Bereiches, akute Schübe chron. Bronchitis, Sinusitis, Otitis media, Pneumonie durch Mykoplasmen, Rickettsien od. Chlamydien. Infekt. d. Urogenitaltraktes, Urethritis durch Chlamydien u. Ureaplasma urealyticum, akute Prostatitis, unkomplizierte Gonorrhoe (insb. b. gleichz. Chlamydieninf.). Infekt. d. weibl. Geschlechtsorgane, Syphilis b. Penicillin-Allergie, Harnwegsinfekt. (nur b. nachgewiesener Empf. d. Erregers). Infekt. d. Magen-Darm-Traktes, Cholera, Yersinien- od. Campylobacter-Infekt. Shigellen-Inf. b. Nachweis d. Empf. Malabsorptionssyndrome wie tropische Sprue u. Morbus Whipple. Ambulante Ther. v. Gallenwegsinfekt. Hauterkr. auch infizierte schwere Formen d. Akne vulg. u. Rosacea, Chlamydien-Konjunktivitis u. Trachom, Borreliosen wie Erythema chronicum migrans u. Lyme-Disease, seltene Infektionen, wie Bartonellose, Brucellose, Listeriose, Ornithose, Rickettsiose, Melioidose, Pest, Granuloma inguinale

Doxymono® 100 Description, Presentation and Dosage

Doxymono® 100 Description

Doxymono® 100 Drug Class Description

Doxycyclin

Doxymono® 100 Drug Description

1 teilbare Tbl. enth.: Doxycyclin 1H2O 104,1 mg/208,2 mg (entspr. 100 mg/200 mg Doxycyclin).

Doxymono® 100 Generic Name

Doxymono® 100/-200 Tabletten

Doxymono® 100 Presentation

Doxymono® 100 Presentation

Doxymono® 100/-200

Doxymono® 100 Manufacturer

betapharm

Related Learning Zones

CSU Knowledge Centre and CME

CSU Knowledge Centre and CME

This Knowledge Centre is intended for allergists, immunologists, dermatologists and other healthcare professionals involved in the treatment and management of Chronic Spontaneous Urticaria (CSU). In the Knowledge Centre, you will find a disease overview, symposium highlights platform, video channel and additional resources including an events calendar and useful external links. This resource has been given a whole new look and feel, intended to improve accessibility and visual appeal. Recent content additions include a frequently asked questions section, case studies from urticaria experts Professor Christian Vestergaard and Professor Torsten Zuberbier and information on the TARGET My Hives app.

LAL-D Knowledge Centre

LAL-D Knowledge Centre

The Lysosomal Acid Lipase (LAL) Deficiency Knowledge Centre contains a range of accurate, informative clinical content for healthcare professionals. The disease awareness section presents epidemiology, pathophysiology and diagnosis information, among others. The treatment section details the drug characteristics, safety and efficacy of sebelipase alfa – the first and only licenced treatment for LAL deficiency. The resources section contains further clinical content including a video channel presenting expert opinions on diagnostic approach and current prognosis.

Developed by EPG Health Media (Europe) Ltd for epgonline.org, in collaboration and with content provided by Alexion Pharma GmbH

Doxymono® 100 Dosage

Doxymono® 100 Adult Dosage

mikrokristalline Cellulose, Magnesiumstearat, Poly(O-carboxymethyl)stärke-Natriumsalz, Povidon, hydriertes Rizinusöl, hochdisp. Siliciumdioxid.

Doxymono® 100 Precautions, Reactions and Contraindications

Doxymono® 100 Special Precautions

Doxymono® 100 Special Precautions

T 15 a, b

Doxymono® 100 Adverse Reactions

Doxymono® 100 Adverse Reactions

T 15

Related Drugs - Infectious Diseases

Back to top